PBYI Stock Forecast: Puma Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$7.05
−0.98% on the day

The median 12-month analyst price target for Puma Biotechnology, Inc. is $8.25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 98 of 100 as at 21 Nov 2026 — among the strongest tenth.

Market cap
$368.1M
Ticker Nerd rank
98/ 100
Median analyst target
$8.25
Analysts covering
1
Revenue$56.5M+7.8% y/y
Operating income$7.6M
Net income$8.2M
Free cash flow$1.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.3%
1M
−34.5%
YTD
+18.5%
1Y
+45.7%
From 52W high
−37.4%
From 52W low
+45.7%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Puma Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
98/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Quality
98
Momentum
90
Accruals
89
Volatility
87
Issuance
83
Growth
42
Revisions
41

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (41): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PBYI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PBYI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12Jan 26Apr 26Jul 26Oct 26PBYIHigh $8.25Median $8.25Low $8.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0
Buy
1
Hold
0
Sell
$8.25
Low
$8.25
Median
$8.25
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026TD CowenMaintainsHold$5.00 → $6.00
28 Feb 2025HC Wainwright & Co.ReiteratesBuy$7.00
23 Dec 2024HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024HC Wainwright & Co.ReiteratesBuy—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
2 Aug 2024HC Wainwright & Co.ReiteratesBuy—
26 July 2024HC Wainwright & Co.ReiteratesBuy—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
20 May 2024HC Wainwright & Co.ReiteratesBuy—
3 May 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.MaintainsBuy—
13 Feb 2024HC Wainwright & Co.ReiteratesBuy—
20 Sept 2023HC Wainwright & Co.ReiteratesBuy—
4 Aug 2023HC Wainwright & Co.ReiteratesBuy—
5 June 2023HC Wainwright & Co.ReiteratesBuy—
5 May 2023HC Wainwright & Co.ReiteratesBuy—
6 Mar 2023HC Wainwright & Co.ReiteratesBuy—
31 Aug 2022HC Wainwright & Co.MaintainsBuy—
5 Aug 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PBYI.

Market Radar

This page is one stock. Monday covers all of them.

PBYI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PBYI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Puma Biotechnology, Inc. returned +45.7% against +6.9% for the S&P 500, dividends included.

PBYI vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26PBYIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PBYI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+22.2%
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.6×

Cheaper than 55% of US stocks

Price / sales
1.6×

Cheaper than 54% of US stocks

Price / book
2.5×

Cheaper than 36% of US stocks

EV / EBITDA
7.4×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−32.7%

Higher than 15% of US stocks

Gross margin
77.9%

Higher than 89% of US stocks

Operating margin
11.3%

Higher than 66% of US stocks

Net margin
10.3%

Higher than 68% of US stocks

Returns & dividend
Return on equity
18.2%

Higher than 79% of US stocks

Return on assets
8.1%

Higher than 88% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Puma Biotechnology, Inc. has a market value of $368.1M and an enterprise value of $264.4M.

  • Revenue in the twelve months to 30 June 2026: $231.2M. The latest quarter grew 7.8% year on year.

  • Net income over the same four quarters: $26.7M, a 11.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.52.

  • Free cash flow in the twelve months to 30 June 2026: $41.2M.

  • Shares outstanding: 51.1M.

  • Trailing P/E: 15.6×; forward P/E: 20.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Puma Biotechnology, Inc. employs 179 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

PBYI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PBYIPuma Biotechnology, Inc.$368.1M98
ASPEAspen Neuroscience, Inc.$361.2M0
PHATPhathom Pharmaceuticals, Inc.$364.9M79
ALECAlector, Inc.$346.2M94
RZLTRezolute, Inc.$375.1M42
YDESYD Bio Ltd.$342.2M3
LYELLyell Immunopharma, Inc.$338.2M80

Take a look at PBYI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Puma Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PBYI

What is the PBYI stock price forecast for 2026-2027?

The median 12-month analyst price target for Puma Biotechnology, Inc. is $8.25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PBYI stock a buy right now?

Of the 1 analyst covering Puma Biotechnology, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Puma Biotechnology, Inc. 98 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PBYI?

As at 21 Nov 2026, Puma Biotechnology, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will PBYI stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $8.25, and Ticker Nerd's factor model ranks Puma Biotechnology, Inc. 98 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PBYI stock forecast for 2030?

No analyst covering Puma Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBYI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.25 to $8.25 over the next 12 months.

How has PBYI stock performed over the past year?

Puma Biotechnology, Inc. returned +45.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Puma Biotechnology, Inc. do?

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care. Its current portfolio centers on NERLYNX, an oral treatment based on neratinib used in specific HER2-positive breast cancer settings, along with alisertib, an investigational oncology candidate being studied across several tumor types.

Company

About Puma Biotechnology, Inc.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care. Its current portfolio centers on NERLYNX, an oral treatment based on neratinib used in specific HER2-positive breast cancer settings, along with alisertib, an investigational oncology candidate being studied across several tumor types. The company works through specialty pharmacy and distributor networks and maintains licensing and collaboration agreements that support the development, manufacture, and commercialization of its cancer-focused products. Puma Biotechnology serves patients and healthcare providers in the United States and select international markets, with an emphasis on targeted therapies for oncology. Based in Los Angeles, California, Puma Biotechnology plays a specialized role in the biotechnology market by concentrating on molecularly targeted cancer treatments and late-stage product commercialization.

CEO Mr. Alan H. Auerbach · 179 employees · United States · https://www.pumabiotechnology.com